Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, September 8, 2017
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
Thu, September 7, 2017
[ Thu, Sep 07th 2017
] - WOPRAI
[ Thu, Sep 07th 2017
] - WOPRAI
[ Thu, Sep 07th 2017
] - WOPRAI
[ Thu, Sep 07th 2017
] - WOPRAI
[ Thu, Sep 07th 2017
] - WOPRAI
Alethia Young Maintained (SRPT) at Buy with Increased Target to $81 on, Sep 7th, 2017
Alethia Young of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $64 to $81 on, Sep 7th, 2017.
Alethia has made no other calls on SRPT in the last 4 months.
There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, all agrees with Alethia's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $33 on, Thursday, July 20th, 2017
